Caption Management, LLC Cassava Sciences Inc Call Options Transaction History

Caption Management, LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	BUY	$23.46 - $36.44 $1.02 Million - $1.58 Million	43,400 Added 86.8%	93,400 $2.25 Million
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $2.09 Million - $3.32 Million	-75,100 Reduced 60.03%	50,000 $1.48 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $1.23 Million - $3.83 Million	75,100 Added 150.2%	125,100 $5.23 Million
Q2 2022 Aug 15, 2022	SELL	$17.22 - $38.47 $516,599 - $1.15 Million	-30,000 Reduced 37.5%	50,000 $1.41 Million
Q1 2022 May 13, 2022	SELL	$32.6 - $53.05 $919,320 - $1.5 Million	-28,200 Reduced 26.06%	80,000 $2.97 Million
Q4 2021 Feb 11, 2022	BUY	$36.77 - $90.91 $301,514 - $745,462	8,200 Added 8.2%	108,200 $4.73 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $3.22 Million - $8.97 Million	100,000 New	100,000 $8.54 Million
Q3 2020 Nov 16, 2020	SELL	$2.86 - $11.51 $340,340 - $1.37 Million	-119,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.04 - $9.64 $242,760 - $1.15 Million	119,000 New	119,000 $366,000

191

13.7M

2.97M

6.55M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $95.4M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.